Sabra Healthcare (SBRA) reported $190.04 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.8%. EPS of $0.38 for the same period compares to $0.13 a year ago.
The reported revenue represents a surprise of -1.08% over the Zacks Consensus Estimate of $192.12 million. With the consensus EPS estimate being $0.38, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sabra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Sabra here>>>
Shares of Sabra have returned -0.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Oct-19 | |
| Sep-09 | |
| Aug-14 | |
| Aug-04 | |
| Aug-04 | |
| Aug-03 | |
| Aug-03 | |
| Jul-23 | |
| Jul-21 | |
| Jul-20 | |
| May-28 | |
| May-01 | |
| Apr-30 | |
| Apr-29 | |
| Apr-29 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite